- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Mariam Lewis on Why Women Are More Vulnerable to Effects From Tobacco
Mariam Lewis, MD, FCCP, a pulmonologist at UF Health and the UF College of Medicine, discusses why women are more sensitive to the effects of tobacco.
Mariam Lewis, MD, FCCP, a pulmonologist at UF Health, and co-medical director, Sleep Lab, in Jacksonville, Florida; and associate professor, Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, at the UF College of Medicine, discusses why women are more sensitive to the effects of tobacco.
Transcript
Why are women more sensitive to the effects of tobacco smoke?
So that's a really good question. It's probably multiple reasons. Genetics plays a factor—so just if you're more susceptible to it genetically. Hormones—we know that women are much more susceptible because of the effects of estrogen. Probably the X chromosome in and of itself. And then the development of the lung is different between girls and boys. And so all of those combined together make it more likely that women are more susceptible to the effects of tobacco compared to men.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
VBID, Heading Into a Third Decade, Looks to Promote Personalization and Access
March 12th 2025Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.
Read More
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More
